Xiang Guo

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 5

Top Topics

Quality Improvement

Ulcerative Colitis

Top Venues

United European gastroenterology journal

Journal of gastroenterology and hepatology

This page only lists publications with an associated author ORCID identifier.

Publications

Julian Panes, Geert R D'Haens, Bruce E Sands, William K K Wu, Nervin Lawendy, Nicole Kulisek, Xiang Guo, Joseph Wu, Ivana Vranic, Remo Panaccione, Severine Vermeire
Analysis of tofacitinib safety in ulcerative colitis from the completed global clinical developmental program up to 9.2 years of drug exposure. United European gastroenterology journal 12 (6) (2024)
Julian Panes, Geert R D'Haens, Bruce E Sands, William K K Wu, Nervin Lawendy, Nicole Kulisek, Xiang Guo, Joseph Wu, Ivana Vranic, Remo Panaccione, Severine Vermeire
Analysis of tofacitinib safety in ulcerative colitis from the completed global clinical developmental program up to 9.2 years of drug exposure. United European gastroenterology journal 12 (6) (2024)
Julian Panes, Geert R D'Haens, Bruce E Sands, William K K Wu, Nervin Lawendy, Nicole Kulisek, Xiang Guo, Joseph Wu, Ivana Vranic, Remo Panaccione, Severine Vermeire
Analysis of tofacitinib safety in ulcerative colitis from the completed global clinical developmental program up to 9.2 years of drug exposure. United European gastroenterology journal 12 (6) (2024)
Julian Panes, Geert R D'Haens, Bruce E Sands, William K K Wu, Nervin Lawendy, Nicole Kulisek, Xiang Guo, Joseph Wu, Ivana Vranic, Remo Panaccione, Severine Vermeire
Analysis of tofacitinib safety in ulcerative colitis from the completed global clinical developmental program up to 9.2 years of drug exposure. United European gastroenterology journal (2024)
Jessica R Allegretti, Krisztina B Gecse, Michael V Chiorean, Marjorie Argollo, Xiang Guo, Nervin Lawendy, Chinyu Su, Rajiv Mundayat, Jerome Paulissen, Leonardo Salese, Peter M Irving
Early recapture of response with tofacitinib 10 mg twice daily in patients with ulcerative colitis in OCTAVE Open following dose reduction or treatment interruption in OCTAVE Sustain. Journal of gastroenterology and hepatology (2023)